BREAKING! Debut Of SARS-CoV-2 BA.4, BA.5 Variants, Recombinant XE Variant And More Than 34 Other Subvariants Heralds Doomsday Scenario!
In the last 14 days, virologists and genomic experts from the around the world (Except in the UK, where certain so called ‘experts’ who are in reality under the payroll of the big pharma, are often giving contradictory statements!) have alarmingly identified a number of new Omicron variants, BA.2 subvariants and third generation subvariants and also BA.2 recombinant variants that are all showing increasing circulation and spread in various different geolocations across the globe.
Thailand Medical News
had already been warning about such a scenario since December 2021 and the debut of many new variants, subvariants and recombinant variants is going to totally change the kinetics of the COVID-19 pandemic as we are going to see more reinfections and coinfections in non-stop cycles and also more new variants produced in these cycles along with sub-lineages that are able to evade vaccine induced immunity, natural immunity and also antivirals and existing therapeutics.
Except for those who are elderly and have existing comorbidities, majority might initially have asymptomatic and mild symptomatic infections as these new variants are able to literally switch off the human host initial immune responses, but they will cause damages to the human host with every infection, causing serious health and medical conditions and we can expect to see an exponential rise in excess deaths from heart failures, strokes, kidney and liver failures, CVST, sepsis, secondary opportunistic infections, accelerated aggressive cancers and accelerated aggressive neurodegenerative conditions.
But alarmingly as well, at least one potentially lethal variant has been identified among this many new sub-lineages (more about this new variant at the end of the article)
Rise Of The BA.4.and BA.5 Variants.
The BA.4 and BA.5 variants were identified by Swiss based biophysicists, Dr Cornelius Roemer.
Both the BA.4 and BA.5 lineages were detected in South Africa where it is now growing in predominance and has also been identified in Germany, Denmark UK and also other European and African countries.
The BA.4/5 share important mutations, like nuc: G12160A, S:L452R, S:F486V but do not have the S:Q493R (in contrast to all other Omicrons).
The BA.4 variant or BA.1.1.529.4 variant
has the following unique mutations: nuc:27788T, nuc:27259C Key mutations: Spike L452R, F486V, 493Q-reversion; N:P151S
COV-spectrum predicts a significant growth advantage over BA.1/2
While the BA.5 variant or BA.1.1.529.5 variant
has the following unique mutations: nuc:27889T, nuc:283
30G Key mutations: Spike L452R, F486V, 493Q-reversion; M:D3N
COV-spectrum predicts a significant growth advantage over BA.1/2.
As of time of publication of this article, the number of sequences showing these two variants in various online sequencing databases such as GISAID are increasing.
More details on both these new BA.4 and BA.5 variants will be provided by Thailand Medical News in coming days.
Debut of XE Variant
The XE variant is one of the many recombinant variants identified recently and is basically a unique combinate of the BA.1 and BA.2 variants. (There are other such recombinant BA.1 and BA.2 variants but the XE possess the unique mutations seen only in this lineage) It is the fifth known recombinant variant involving the Omicron variant. https://github.com/cov-lineages/pango-designation/issues/454
The British Health Security Agency confirmed 637 cases of XE, the earliest on Jan. 19.
The British Health Security Agency identified XD and XF as combinations of delta and omicron BA.1.
In the U.K., 38 cases of XF have been identified, all before mid-February, and there is no evidence that this version of the virus is being transmitted within the country.
Other BA.1/BA.2 Recombinant Variants
Forty-nine cases of XD have been reported in global databases, the majority in France.
Since January to now, XE has infected about 600 people in the U.K. It’s not clear whether XE is more contagious than BA.2, and there is no indication it can cause more severe disease.
However, XE has shown a variable growth rate and is now being detected across the world including India, United States, Canada, Germany, Thailand, Singapore etc.
So far there is not enough evidence to draw conclusions about transmissibility, severity or vaccine effectiveness or true growth advantage.
Other recombinant BA.1/BA.2 variants at play now include:
XP - BA.1.1/BA.2 Recombinant (Scotland, UK)
XQ- BA.1.1/BA.2 Recombinant (England, Wales)
XR- BA.1.1/BA.2 Recombinant (Wales)
More BA.2 Subvariants ie BA.2.8 to BA.2.12
Continuing from our early reports about the rise of various BA.2.2 subvariants like BA.2.2 to that was causing a huge outbreak in Hong Kong to the BA.2.7 subvariant found in the United States, we continue to report on the various new BA.2 sub-variants that have emerged. https://www.thailandmedical.news/news/breaking-american-scientist-from-arkansas-state-university-alerts-scientific-community-of-numerous-ba-2-subvariants-that-have-alarmingly-emerged
BA.2.8 (B.1.1.529.2.8) variant
predominantly found in Scotland, Defining mutations: Orf3a:A31T + Nuc:T21048C (2400+ sequences) then Orf3a:T9K (2000+ sequences).
COV-spectrum predicts a global growth advantage of 34% over BA.2 and >100% over BA.1.1
BA.2.9 (B.1.1.529.2.9) variant
, prevalent in Denmark and Poland.
Key mutation: ORF3a: H78Y
COV-spectrum predicts a global growth advantage of -15% over BA.2 and 15% over BA.1.1
BA.2.10 (BA.1.1.529.1.10) variant
, prevalent in India but also found in Singapore and Australia. Key mutation: ORF1b:S959P
COV-spectrum predicts a global growth advantage of -15% over BA.2 and 15% over BA.1.1
BA.2.11 (BA.1.1.529.2.11) variant
, prevalent in France. Key mutations: ORF1a:S2519P+S:L452R
COV-spectrum predicts a global growth advantage of 55% over BA.2 and 149% over BA.1.1 (sample size is low - these numbers are not reliable yet)
BA.2.12 (BA.1.1.529.2.12) variant
, prevalent in Canada and also found elsewhere in Europe. Key mutations: Spike S704L
COV-spectrum predicts a global growth advantage of 3% over BA.2 and 47% over BA.1.1
Third Generation BA.2 Sub-variants
BA.2.3.1 variant aka B.1.1.5184.108.40.206 variant
, prevalent in Japan Key mutations: Spike: Q677E
COV-spectrum predicts a growth advantage of 15% over BA.2 and 59% over BA.1.1 in Japan
BA.2.3.2 variant aka B.1.1.5220.127.116.11 variant
, prevalent in Vietnam and Japan. Key Mutation: (Envelope Protein :S55F)
COV-spectrum predicts a global growth advantage of 12% over BA.2 and 64% over BA.1.1
BA.2.10.1 variant aka B.1.1.518.104.22.168 variant
, prevalent in Singapore and other countries. Key mutations: Spike: G798D
COV-spectrum predicts a growth advantage of 11% over BA.2 and 43% over BA.1.1 in Singapore
BA.2.12.1 variant aka BA.1.1.529.12.1 variant
, prevalent in USA and some parts of Europe. Key mutation: Spike: L452Q) 47 of the 213 BA.2 sequences from New York in the last 15 days carry this Spike L452Q mutation. This mutation was last found in the Lambda variant!
COV-spectrum predicts a global growth advantage of 32% over BA.2 and 105% over BA.1.1
Other Concerning Emerging BA.2 Variants:
BA.2 variant with S:L452R and S:F486V (79 sequences as of 2022-04-05, mainly South Africa)
BA.2 with N:Q39L & ORF1a:S2535L in UK
BA.2 with Spike P681R mutation (9 sequences uploaded last week from Denmark)
BA.2 with with S:K356R and also has orf1a: s2193f mutations in Norway and UK
A potential Omicron BA.6 Variant identified in Peru And Chile with ORF1ab:E973K mutation.
Potential Lethal BA.2 Variants:
The BA.2.12.1 variant aka BA.1.1.529.12.1 variant that has been identified in New York and many other parts of USA could become the most lethal BA.2 sub-variant to emerge so far as besides being very transmissible, it is possess the Spike mutation : L452Q which was last seen in the Lambda variant. https://www.cell.com/cell-reports/pdf/S2211-1247(21)01722-8.pdf
The L452Q mutation is known for increased cell fusogenicity, causing disease severity. https://www.sciencedirect.com/science/article/pii/S2211124721017228
To date all patients identified with this new variant are either in ICU wards or have died!
Mutation To Watch Out For: L452R
mutation which is starting to appear on may BA.2 subvariants and third generation variants and also in the new BA.4 and BA.5 variants is another concerning mutation that also increases fusogenicity and infectivity.It is seen in many emerging variants in UK, South Africa, Denmark and the rest of Europe.
The increased fusogenicity is known to increase disease severity and mortality rates. For those who survive, long COVID conditions are typically severe with extreme fatigue and debilitating. https://www.nature.com/articles/s41392-022-00941-z
More Variants To Emerge
These are only some of the BA.2 subvariants and third generation variants or recombinant variants that have emerged, there are many Delta subvariants and third and fourth generation variants also emerging coupled with many potential new clades appearing soon due to the current kinetics of the COVID-19 pandemic and the lifting of measures and travel restrictions and also less testing and sequencings.
Thailand Medical News expects more concerning variants to appear in the United Kingdom, The United States, Germany, Denmark, Thailand and the African continent in the next few weeks.
The rest of 2022 is going to be fun times as while many governments lift restrictions and cut down on testing and also try to conceal the true COVID-19 figures, excess mortality rates are going to increase astronomically! Perhaps it is for the better as many are living in denial or are simply so stupid that they really do not deserve being saved!
For more on the BA.4, BA.5 and other BA.2 subvariants and recombinant variants, keep on logging to Thailand Medical News.
PS: Please share this article with as many as possible as so many individuals are not even aware of the current situation of the pandemic and those controlling the COVID-19 narratives are not happy with us writing about emerging variants and their threats!